Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human ...

INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

Cassava Sciences' stock craters after Alzheimer's disease trial fails to meet its goals. MarketWatch Nov 25, 2024, 3:43:00 PM. Cassava Sciences Shares Lower Premarket on $40 Million Penalty to ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug, ...

Cassava Sciences is nearing a Phase 3 readout for its Alzheimer's drug, lecanemab, despite facing a scandal involving the SEC. Learn more about the latest updates on donanemab and the company's ...

In an era where global markets celebrate cultural identity and originality, Ghana stands at a critical crossroads. We have introduced marketing as a discipline in our universities, invested heavily in ...

Across the seven local government areas of the southern senatorial district of Kwara State, communities live in fear of foreign elements.